Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.40 |
| ▸ | FYN | P06241 | 4/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 3/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2034283 | 0.93 | PDK2 (0.46) | PDK2ADRA2AADRA1APIK3CGKDM5A | |
| SCHEMBL2031881 | 0.87 | PDK2 (0.42) | PDK2ADRA2AADRA1APIK3CGKDM5A | |
| SCHEMBL2035430 | 0.85 | JAK2 (0.46) | PDK2ADRA2AADRA1APIK3CGKDM5A | |
| SCHEMBL2034739 | 0.85 | PIK3CG (0.44) | PDK2ADRA2AADRA1APIK3CGKDM5A | |
| SCHEMBL2009206 | 0.85 | GRM5 (0.46) | PDK2ADRA2AADRA1APIK3CGKDM5A | |
| SCHEMBL2034297 | 0.84 | KDM5A (0.44) | PDK2ADRA2AADRA1APIK3CGKDM5A | |
| SCHEMBL2029037 | 0.84 | TDP2 (0.45) | PDK2ADRA2AADRA1APIK3CGKDM5A | |
| SCHEMBL12543974 | 0.83 | KAT6A (0.46) | PDK2ADRA2AADRA1APIK3CGKDM5A | |
| SCHEMBL2034154 | 0.81 | NR4A2 (0.48) | PDK2PIK3CGKDM5AKDM4CKDM5B | |
| SCHEMBL2032150 | 0.80 | NR4A2 (0.58) | PIK3CGKDM5AKDM4CKDM5BKAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507238-B1 | DIPHENYL-PYRAZOLOPYRIDINE COMPOUNDS, THEIR PREPARATION AND THEIR APPLICATION AS MODULATORS OF THE NUCLEAR RECEPTOR NOT | SANOFI SA (FR) | 2013-07-31 | — | — | EP | claimed |
| EP-2507238-A1 | DIPHENYL-PYRAZOLOPYRDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | SANOFI (FR) | 2012-10-10 | — | — | EP | claimed |
| US-20120245164-A1 | DIPHENYL-PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | SANOFI (FR) | 2012-09-27 | — | — | US | claimed |
| WO-2011067544-A1 | DIPHENYL-PYRAZOLOPYRDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | SANOFI-AVENTIS (FR) | 2011-06-09 | — | — | WO | claimed |
| US-8680096-B2 | Diphenyl-pyrazolopyridine derivatives, preparation thereof, and use thereof as nuclear receptor not modulators | SANOFI-AVENTIS (FR) | 2014-03-25 | — | — | US | disclosed |
| EP-2507238-B1 | DIPHENYL-PYRAZOLOPYRIDINE COMPOUNDS, THEIR PREPARATION AND THEIR APPLICATION AS MODULATORS OF THE NUCLEAR RECEPTOR NOT | SANOFI SA (FR) | 2013-07-31 | — | — | EP | disclosed |
| EP-2507238-A1 | DIPHENYL-PYRAZOLOPYRDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | SANOFI (FR) | 2012-10-10 | — | — | EP | disclosed |
| US-20120245164-A1 | DIPHENYL-PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| WO-2011067544-A1 | DIPHENYL-PYRAZOLOPYRDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | SANOFI-AVENTIS (FR) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245164-A1 | DIPHENYL-PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | NR4A3, NCOR1, NR4A2 | PDK2 1996/4885ADRA2A 542/4885ADRA1A 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.